(PharmaNewsWire.Com, July 25, 2017 ) Osteoporosis, or porous bone, is a disease characterised by low bone density and structural deterioration of bone tissue, leading to fragile bones. This increases the risk of fractures. Osteoporosis mainly affects women, but can also affect men. In women, bone loss occurs very rapidly in the first few years after menopause and continues through the postmenopausal stage. Osteoporosis progresses when bone resorption occurs too quickly or when replacement occurs too slowly. Risk factors for osteoporosis that cannot be controlled include gender, age, body size (low body weight), ethnicity, and family history. Risk factors that can be controlled include sex hormones, medication use, calcium and vitamin intake, alcohol intake, and smoking.
Publisher's analysts forecast the osteoporosis drugs market in BRIC nations to grow at a CAGR of 17.43% over the period 2014-2019.
Covered in this report This report covers the present scenario and the growth prospects of the osteoporosis drugs market in BRIC nations for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various pharmaceutical products used in the treatment of osteoporosis. Pharmaceutical products are classified as branded and generic drugs.
Publisher's report, Osteoporosis Drugs Market in BRIC Nations 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers Brazil, Russia, India, and China; it also covers the landscape of the osteoporosis drugs market in BRIC nations and its growth prospects in the coming years. The report includes a discussion on the key vendors operating in this market.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: